Manager TitleAgeSince
President 61 2023-05-31
Chief Tech/Sci/R&D Officer - 2020-12-31
Chief Tech/Sci/R&D Officer - -
Date Insider Type Main position Quantity % Market Cap. Importance
6/1/23
Tang Capital Management LLC
OthersCompany 4,394,800 11.1936%
6/1/23 Issuer sale

Chief Operating Officer

247,717 0.6309%
6/1/23 Issuer sale

Director

60,342 0.1537%
Change 5-day change 1-year change 3-year change Capi.($)
-5.73%-15.43% - - 58.11M
-2.49%-6.35%+51.07%+64.95% 65.42B
-0.63%-3.81%+6.95%+88.55% 58.91B
-2.37%-2.22%+22.96%+83.44% 55.24B
-2.09%-5.73%+12.42%+109.00% 45.66B
-1.57%-6.65%+13.99%+20.56% 41.29B
-0.93%+1.67%+20.83%+45.03% 36.82B
+0.68%-6.58%+130.32%+640.68% 34.48B
-0.80%-1.73%+75.29%+56.47% 32.5B
-1.91%+17.41%-28.74%+477.82% 31.69B
Average -1.65%-0.66%+33.90%+176.28% 45B
Weighted average by Cap. -1.33%-1.28%+32.24%+150.81%
Logo TCR2 Therapeutics Inc.
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. The Company's T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. Its lead TRuC-T cell, which targets solid tumors is gavocabtagene autoleucel (gavo-cel). The Company completed the Phase I portion of its Phase I/II clinical trial for gavo-cel to treat patients with non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Its other product candidates include TC-510 and TC-520. Its TC-510 is a TRuC-T cell targeting mesothelin-expressing solid tumors which incorporates a PD-1:CD28 chimeric switch receptor. Its TC-520 is the Company's TRuC-T cell targeting CD-70-expressing solid and liquid tumors which incorporates IL-15 pathway enhancements designed to improve T-cell persistence.
Employees
58
  1. Stock Market
  2. Stocks
  3. TCRR Stock